Table 2.

Clinical characteristics of patients presented at the VTBs

Tumor entity	Presented cases		Presence of metastases		Prior surgery		Prior radiotherapy		Prior chemotherapy or targeted therapy		Prior or ongoing ICPI therapy
	n	%	n	%	n	(%)	n	(%)	n	(%)	n	(%)
Lung cancer	34	467	33	97	11	32	18	53	27	79	27	79
Melanoma	14	19	13	93	13	93	4	29	6	43	11	79
Bladder cancer	10	14	9	90	9	90	5	50	8	80	5	50
Renal cell cancer	5	7	5	100	5	100	2	40	4	80	2	40
Colorectal cancer	2	3	2	100	1	50	1	50	2	100	1	50
Laryngeal cancer	2	3	2	100	1	50	2	100	2	100	0	0
Anal carcinoma	1	1	1	100	0	0	1	100	1	100	1	100
Merkel cell carcinoma	1	1	1	100	1	100	0	0	0	0	1	100
Mesopharyngeal cancer	1	1	0	0	1	100	1	100	1	100	0	0
Salivary ductal carcinoma	1	1	1	100	1	100	1	100	1	100	0	0
Uveal melanoma	1	1	1	100	1	100	1	100	1	100	1	100
CUP	1	1	–	–	–	–	–	–	–	–	–	–
Total	73	100	68	93	44	60	36	49	53	63	49	67

CUP carcinoma of unknown primary, ICPI immune checkpoint inhibitor, VTB virtual tumor board